France's Mauna Kea Technologies, which makes the world's smallest microscope used to examine the inside of the human body, is hoping to raise about $67.7 million from its initial public offering. As Reuters notes, the company is moving ahead with its plans even though more than 15 European IPO deals have failed this year, including Agendia, a Dutch maker of breast cancer tests, and Verallia, Saint-Gobain's glass container unit. Mauna Kea, which is set to list on the NYSE Euronext, said the price range of its IPO would be between €10.65 and €13 a share and that the offer would close July 4. Story